<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Antipsychotics | Domain 9 | MasteryPage</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Instrument+Serif:ital@0;1&family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-primary: #09090b; --bg-secondary: #0f0f11; --bg-tertiary: #18181b; --bg-card: #1c1c1f;
      --text-primary: #fafafa; --text-secondary: #a1a1aa; --text-muted: #71717a;
      --accent: #ef4444; --accent-dim: rgba(239, 68, 68, 0.15);
      --border: rgba(255, 255, 255, 0.06); --gradient-gold: linear-gradient(135deg, #f59e0b 0%, #d97706 100%);
      --radius-sm: 8px; --radius-md: 12px; --radius-lg: 16px;
      --font-display: 'Instrument Serif', Georgia, serif; --font-body: 'Inter', -apple-system, sans-serif;
    }
    * { margin: 0; padding: 0; box-sizing: border-box; }
    body { font-family: var(--font-body); background: var(--bg-primary); color: var(--text-primary); line-height: 1.7; }
    .top-nav { position: fixed; top: 0; left: 0; right: 0; height: 72px; background: rgba(9, 9, 11, 0.95); backdrop-filter: blur(20px); border-bottom: 1px solid var(--border); z-index: 1000; display: flex; align-items: center; padding: 0 32px; }
    .nav-left { display: flex; align-items: center; gap: 24px; }
    .logo { display: flex; align-items: center; gap: 10px; text-decoration: none; }
    .logo-icon { width: 36px; height: 36px; background: var(--gradient-gold); border-radius: 10px; display: flex; align-items: center; justify-content: center; }
    .logo-icon svg { width: 20px; height: 20px; color: var(--bg-primary); }
    .logo-text { font-family: var(--font-display); font-size: 1.35rem; color: var(--text-primary); }
    .breadcrumb { display: flex; align-items: center; gap: 8px; font-size: 0.9rem; color: var(--text-muted); }
    .breadcrumb a { color: var(--text-secondary); text-decoration: none; }
    .breadcrumb a:hover { color: var(--accent); }
    .breadcrumb svg { width: 16px; height: 16px; }
    .content-wrapper { padding-top: 72px; display: flex; min-height: 100vh; }
    .sidebar { width: 280px; background: var(--bg-secondary); border-right: 1px solid var(--border); position: fixed; top: 72px; bottom: 0; overflow-y: auto; padding: 24px 0; }
    .sidebar-header { padding: 0 20px 16px; border-bottom: 1px solid var(--border); margin-bottom: 16px; }
    .sidebar-title { font-size: 0.75rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 8px; }
    .domain-title { font-size: 1rem; font-weight: 600; color: var(--accent); }
    .chapter-list { list-style: none; }
    .chapter-item { border-bottom: 1px solid var(--border); }
    .chapter-link { display: flex; align-items: center; gap: 12px; padding: 14px 20px; color: var(--text-secondary); text-decoration: none; font-size: 0.9rem; transition: all 0.2s ease; }
    .chapter-link:hover { background: var(--bg-tertiary); color: var(--text-primary); }
    .chapter-link.active { background: var(--accent-dim); color: var(--accent); border-left: 3px solid var(--accent); }
    .chapter-number { width: 24px; height: 24px; border-radius: 50%; background: var(--bg-tertiary); display: flex; align-items: center; justify-content: center; font-size: 0.75rem; font-weight: 600; flex-shrink: 0; }
    .sidebar-section-label { padding: 12px 20px 6px; font-size: 0.7rem; text-transform: uppercase; letter-spacing: 0.08em; color: var(--accent); font-weight: 600; }
    .main-content { margin-left: 280px; flex: 1; padding: 48px 64px; max-width: 900px; }
    .chapter-header { margin-bottom: 48px; }
    .chapter-badge { display: inline-flex; align-items: center; gap: 8px; padding: 6px 12px; background: var(--bg-tertiary); border: 1px solid var(--border); border-radius: 20px; font-size: 0.8rem; color: var(--text-muted); margin-bottom: 16px; }
    h1 { font-family: var(--font-display); font-size: 2.5rem; margin-bottom: 16px; line-height: 1.2; }
    .chapter-meta { display: flex; gap: 24px; color: var(--text-muted); font-size: 0.9rem; }
    .coming-soon-container { display: flex; flex-direction: column; align-items: center; justify-content: center; padding: 80px 40px; text-align: center; }
    .coming-soon-icon { width: 80px; height: 80px; background: var(--accent-dim); border-radius: 50%; display: flex; align-items: center; justify-content: center; margin-bottom: 32px; }
    .coming-soon-icon svg { width: 40px; height: 40px; color: var(--accent); }
    .coming-soon-title { font-family: var(--font-display); font-size: 2rem; margin-bottom: 16px; color: var(--text-primary); }
    .coming-soon-text { color: var(--text-secondary); font-size: 1.1rem; max-width: 500px; margin-bottom: 32px; line-height: 1.8; }
    .coming-soon-note { background: var(--bg-card); border: 1px solid var(--border); border-radius: var(--radius-md); padding: 20px 24px; color: var(--text-muted); font-size: 0.9rem; }
    .nav-buttons { display: flex; justify-content: space-between; margin-top: 64px; padding-top: 32px; border-top: 1px solid var(--border); }
    .nav-btn { display: flex; align-items: center; gap: 12px; padding: 16px 24px; background: var(--bg-card); border: 1px solid var(--border); border-radius: var(--radius-md); text-decoration: none; color: var(--text-secondary); transition: all 0.2s ease; }
    .nav-btn:hover { border-color: var(--accent); color: var(--text-primary); }
    .nav-btn-label { font-size: 0.8rem; color: var(--text-muted); }
    .nav-btn-title { font-weight: 600; color: var(--text-primary); }
    .content-section { margin-bottom: 48px; }
    .content-section h2 { font-family: var(--font-display); font-size: 1.8rem; margin-bottom: 20px; padding-bottom: 12px; border-bottom: 1px solid var(--border); }
    .content-section h3 { font-size: 1.25rem; font-weight: 600; margin: 28px 0 12px; color: var(--text-primary); }
    .content-section h4 { font-size: 1.05rem; font-weight: 600; margin: 20px 0 8px; color: var(--text-secondary); }
    .content-section p { color: var(--text-secondary); margin-bottom: 16px; font-size: 0.95rem; }
    .content-section ul, .content-section ol { color: var(--text-secondary); margin: 0 0 16px 24px; font-size: 0.95rem; }
    .content-section li { margin-bottom: 6px; }
    .key-term { color: var(--accent); font-weight: 600; }
    .definition-box { background: var(--bg-card); border-left: 3px solid var(--accent); border-radius: 0 var(--radius-sm) var(--radius-sm) 0; padding: 16px 20px; margin: 16px 0; }
    .definition-box strong { color: var(--text-primary); }
    .definition-box p { margin-bottom: 0; }
    .example-box { background: rgba(245, 158, 11, 0.06); border-left: 3px solid #f59e0b; border-radius: 0 var(--radius-sm) var(--radius-sm) 0; padding: 16px 20px; margin: 16px 0; }
    .example-box strong { color: #f59e0b; }
    .example-box p { margin-bottom: 0; }
    .clinical-note { background: rgba(59, 130, 246, 0.08); border-left: 3px solid #3b82f6; border-radius: 0 var(--radius-sm) var(--radius-sm) 0; padding: 16px 20px; margin: 16px 0; }
    .clinical-note strong { color: #3b82f6; }
    .clinical-note p { margin-bottom: 0; }
    .citation { font-size: 0.85rem; color: var(--text-muted); font-style: italic; }
    table { width: 100%; border-collapse: collapse; margin: 16px 0; font-size: 0.9rem; }
    th { background: var(--bg-tertiary); color: var(--text-primary); padding: 10px 14px; text-align: left; border: 1px solid var(--border); font-weight: 600; }
    td { padding: 10px 14px; border: 1px solid var(--border); color: var(--text-secondary); }
    @media (max-width: 1024px) { .sidebar { display: none; } .main-content { margin-left: 0; padding: 32px 24px; } }
    .chapter-actions { display: flex; gap: 12px; margin-bottom: 32px; flex-wrap: wrap; }
    .action-btn { display: inline-flex; align-items: center; gap: 8px; padding: 10px 20px; border-radius: 8px; font-size: 0.85rem; font-weight: 500; text-decoration: none; transition: all 0.2s ease; }
    .flashcard-btn { background: var(--bg-tertiary); border: 1px solid var(--border-light); color: var(--text-secondary); }
    .flashcard-btn:hover { background: var(--bg-card); color: var(--text-primary); border-color: var(--accent); }
    .quiz-btn { background: var(--bg-tertiary); border: 1px solid var(--border-light); color: var(--text-secondary); }
    .quiz-btn:hover { background: var(--bg-card); color: var(--text-primary); border-color: var(--accent); }
    .mastery-btn { background: linear-gradient(135deg, #f59e0b 0%, #ef4444 100%); border: none; color: #fff; font-weight: 600; box-shadow: 0 2px 12px rgba(245, 158, 11, 0.3); }
    .mastery-btn:hover { box-shadow: 0 4px 20px rgba(245, 158, 11, 0.5); transform: translateY(-1px); }
    .upgrade-modal-overlay { display:none; position:fixed; top:0; left:0; right:0; bottom:0; background:rgba(0,0,0,0.7); z-index:1000; align-items:center; justify-content:center; }
    .upgrade-modal-overlay.visible { display:flex; }
    .upgrade-modal { background:var(--bg-card); border:1px solid var(--border); border-radius:var(--radius-lg,16px); padding:40px; max-width:420px; width:90%; text-align:center; }
    .upgrade-modal-icon { width:64px; height:64px; margin:0 auto 20px; background:linear-gradient(135deg,#f59e0b 0%,#ef4444 100%); border-radius:50%; display:flex; align-items:center; justify-content:center; }
    .upgrade-modal-icon svg { color:#fff; }
    .upgrade-modal h3 { font-size:1.25rem; margin-bottom:8px; color:var(--text-primary); }
    .upgrade-modal p { color:var(--text-secondary); margin-bottom:24px; font-size:0.9rem; line-height:1.6; }
    .upgrade-modal-actions { display:flex; gap:12px; }
    .upgrade-modal-actions a, .upgrade-modal-actions button { flex:1; padding:12px; border-radius:8px; font-size:0.85rem; font-weight:600; cursor:pointer; text-decoration:none; text-align:center; border:none; }
    .upgrade-modal .btn-dismiss { background:var(--bg-tertiary); color:var(--text-secondary); border:1px solid var(--border); }
    .upgrade-modal .btn-upgrade { background:linear-gradient(135deg,#f59e0b 0%,#ef4444 100%); color:#fff; }
  </style>
</head>
<body>
  <nav class="top-nav">
    <div class="nav-left">
      <a href="../../index.html" class="logo">
        <div class="logo-icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5"><path d="M12 2L2 7l10 5 10-5-10-5zM2 17l10 5 10-5M2 12l10 5 10-5"/></svg></div>
        <span class="logo-text">MasteryPage</span>
      </a>
      <div class="breadcrumb">
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        <a href="../../textbook.html">Textbook</a>
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        <a href="index.html">Domain 9</a>
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        <span>Antipsychotics</span>
      </div>
    </div>
  </nav>
  <div class="content-wrapper">
    <aside class="sidebar">
      <div class="sidebar-header">
        <div class="sidebar-title">Domain 9</div>
        <div class="domain-title">Psychopharmacology &amp; Ethics</div>
      </div>
      <ul class="chapter-list">
        <li class="chapter-item"><a href="index.html" class="chapter-link"><span class="chapter-number">0</span>Overview</a></li>
        <li class="sidebar-section-label">Part A: APA Ethics Code</li>
        <li class="chapter-item"><a href="ethics-overview.html" class="chapter-link"><span class="chapter-number">A0</span>Overview & Principles</a></li>
        <li class="chapter-item"><a href="resolving-ethical-issues.html" class="chapter-link"><span class="chapter-number">A1</span>Resolving Ethical Issues</a></li>
        <li class="chapter-item"><a href="competence.html" class="chapter-link"><span class="chapter-number">A2</span>Competence</a></li>
        <li class="chapter-item"><a href="human-relations.html" class="chapter-link"><span class="chapter-number">A3</span>Human Relations</a></li>
        <li class="chapter-item"><a href="privacy-confidentiality.html" class="chapter-link"><span class="chapter-number">A4</span>Privacy & Confidentiality</a></li>
        <li class="chapter-item"><a href="advertising.html" class="chapter-link"><span class="chapter-number">A5</span>Advertising</a></li>
        <li class="chapter-item"><a href="record-keeping-fees.html" class="chapter-link"><span class="chapter-number">A6</span>Record Keeping & Fees</a></li>
        <li class="chapter-item"><a href="education-training.html" class="chapter-link"><span class="chapter-number">A7</span>Education & Training</a></li>
        <li class="chapter-item"><a href="research-publication.html" class="chapter-link"><span class="chapter-number">A8</span>Research & Publication</a></li>
        <li class="chapter-item"><a href="assessment-ethics.html" class="chapter-link"><span class="chapter-number">A9</span>Assessment</a></li>
        <li class="chapter-item"><a href="therapy-ethics.html" class="chapter-link"><span class="chapter-number">A10</span>Therapy</a></li>
        <li class="sidebar-section-label">Part B: Psychopharmacology</li>
        <li class="chapter-item"><a href="pharma-foundations.html" class="chapter-link"><span class="chapter-number">B0</span>Pharmacological Foundations</a></li>
        <li class="chapter-item"><a href="antidepressants.html" class="chapter-link"><span class="chapter-number">B1</span>Antidepressants</a></li>
        <li class="chapter-item"><a href="antipsychotics.html" class="chapter-link active"><span class="chapter-number">B2</span>Antipsychotics</a></li>
        <li class="chapter-item"><a href="anxiolytics-sedatives.html" class="chapter-link"><span class="chapter-number">B3</span>Anxiolytics & Sedatives</a></li>
        <li class="chapter-item"><a href="mood-stabilizers.html" class="chapter-link"><span class="chapter-number">B4</span>Mood Stabilizers</a></li>
        <li class="chapter-item"><a href="stimulants-adhd.html" class="chapter-link"><span class="chapter-number">B5</span>Stimulants & ADHD Meds</a></li>
        <li class="sidebar-section-label">Appendix</li>
        <li class="chapter-item"><a href="professional-issues.html" class="chapter-link"><span class="chapter-number">+</span>Professional Issues</a></li>
      </ul>
    </aside>
    <main class="main-content">
      <header class="chapter-header">
        <div class="chapter-badge">Chapter B2 of 17</div>
        <h1>Antipsychotics</h1>
        <div class="chapter-meta">
          <span>Typical vs atypical, D2 blockade, side effects</span>
        </div>
      </header>
      <div class="chapter-actions">
        <a href="javascript:void(0)" onclick="chapterAction('flashcards')" class="action-btn flashcard-btn">
          <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><rect x="2" y="3" width="20" height="14" rx="2"/><line x1="8" y1="21" x2="16" y2="21"/><line x1="12" y1="17" x2="12" y2="21"/></svg>
          Flashcards
        </a>
        <a href="javascript:void(0)" onclick="chapterAction('quiz-fundamental', 9)" class="action-btn quiz-btn">
          <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 11l3 3L22 4"/><path d="M21 12v7a2 2 0 01-2 2H5a2 2 0 01-2-2V5a2 2 0 012-2h11"/></svg>
          Quick Quiz: Fundamental
        </a>
        <a href="javascript:void(0)" onclick="chapterAction('advanced-learning', 9)" class="action-btn mastery-btn">
          <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polygon points="12 2 15.09 8.26 22 9.27 17 14.14 18.18 21.02 12 17.77 5.82 21.02 7 14.14 2 9.27 8.91 8.26 12 2"/></svg>
          Advanced Learning
        </a>
      </div>
<section class="content-section">
        <h2>Introduction to Antipsychotic Medications</h2>
        <p>Antipsychotic medications (also called neuroleptics) are the primary pharmacological treatment for <span class="key-term">schizophrenia</span> and other psychotic disorders. They are also used for bipolar disorder, severe agitation, Tourette's disorder, and as adjuncts for treatment-resistant depression. Antipsychotics are divided into two main classes: <strong>first-generation (typical)</strong> and <strong>second-generation (atypical)</strong>.</p>
        <p>For the EPPP, understanding the differences between these two classes -- particularly their mechanisms of action, side effect profiles, and the major adverse effects (EPS, tardive dyskinesia, NMS, and metabolic syndrome) -- is essential.</p>
      </section>

      <section class="content-section">
        <h2>The Dopamine Hypothesis of Schizophrenia</h2>
        <p>The <span class="key-term">dopamine hypothesis</span> proposes that schizophrenia symptoms result from dysregulated dopamine activity in the brain:</p>
        <ul>
          <li><strong>Positive symptoms</strong> (hallucinations, delusions, disorganized thought) are associated with <em>excess dopamine activity</em> in the <span class="key-term">mesolimbic pathway</span></li>
          <li><strong>Negative symptoms</strong> (flat affect, avolition, alogia, anhedonia) are associated with <em>reduced dopamine activity</em> in the <span class="key-term">mesocortical pathway</span> (prefrontal cortex)</li>
        </ul>
        <p>This helps explain why typical antipsychotics, which broadly block dopamine D2 receptors, effectively treat positive symptoms but often worsen negative symptoms and cause movement disorders (due to dopamine blockade in the nigrostriatal pathway).</p>
        <div class="definition-box">
          <strong>Four Dopamine Pathways</strong>
          <p><strong>Mesolimbic:</strong> Excess dopamine leads to positive symptoms. <strong>Mesocortical:</strong> Reduced dopamine leads to negative and cognitive symptoms. <strong>Nigrostriatal:</strong> Dopamine blockade here causes EPS and tardive dyskinesia. <strong>Tuberoinfundibular:</strong> Dopamine blockade here increases prolactin, causing hyperprolactinemia.</p>
        </div>
      </section>

      <section class="content-section">
        <h2>First-Generation (Typical) Antipsychotics</h2>
        <p>First-generation antipsychotics (FGAs) work primarily by blocking <span class="key-term">dopamine D2 receptors</span>. They are classified by potency, which determines their side effect profile.</p>

        <h3>High-Potency Typical Antipsychotics</h3>
        <p>Require lower doses; greater risk of EPS; lower risk of sedation and anticholinergic effects.</p>
        <table>
          <tr><th>Generic Name</th><th>Brand Name</th><th>Notable Features</th></tr>
          <tr><td>Haloperidol</td><td>Haldol</td><td>Most commonly used high-potency typical; available in decanoate (long-acting injectable) form; high EPS risk</td></tr>
          <tr><td>Fluphenazine</td><td>Prolixin</td><td>Also available as long-acting decanoate; high EPS risk</td></tr>
          <tr><td>Thiothixene</td><td>Navane</td><td>High potency; primarily D2 blockade</td></tr>
          <tr><td>Pimozide</td><td>Orap</td><td>FDA-approved for Tourette's disorder; QT prolongation risk</td></tr>
        </table>

        <h3>Low-Potency Typical Antipsychotics</h3>
        <p>Require higher doses; lower risk of EPS; greater sedation, anticholinergic effects, and orthostatic hypotension.</p>
        <table>
          <tr><th>Generic Name</th><th>Brand Name</th><th>Notable Features</th></tr>
          <tr><td>Chlorpromazine</td><td>Thorazine</td><td>First antipsychotic discovered (1950s); highly sedating; photosensitivity; corneal deposits with chronic use; "benchmark" drug (100 mg = standard unit for potency comparisons)</td></tr>
          <tr><td>Thioridazine</td><td>Mellaril</td><td>Highest risk of retinitis pigmentosa; QT prolongation; restricted use due to cardiac risks</td></tr>
        </table>
      </section>

      <section class="content-section">
        <h2>Extrapyramidal Symptoms (EPS)</h2>
        <p><span class="key-term">Extrapyramidal symptoms (EPS)</span> are movement disorders caused by dopamine D2 blockade in the nigrostriatal pathway. They are most common with high-potency typical antipsychotics.</p>
        <table>
          <tr><th>EPS Type</th><th>Onset</th><th>Features</th><th>Treatment</th></tr>
          <tr><td><strong>Acute dystonia</strong></td><td>Hours to days</td><td>Sustained muscle contractions (torticollis, oculogyric crisis, opisthotonus); can be life-threatening if laryngeal muscles affected</td><td>Anticholinergics (benztropine/Cogentin, diphenhydramine/Benadryl)</td></tr>
          <tr><td><strong>Akathisia</strong></td><td>Days to weeks</td><td>Subjective restlessness; inability to sit still; often mistaken for agitation</td><td>Beta-blockers (propranolol), benzodiazepines, dose reduction</td></tr>
          <tr><td><strong>Parkinsonism (pseudoparkinsonism)</strong></td><td>Weeks to months</td><td>Bradykinesia, rigidity, resting tremor, shuffling gait, mask-like facies</td><td>Anticholinergics (benztropine); amantadine; dose reduction</td></tr>
          <tr><td><strong>Tardive dyskinesia</strong></td><td>Months to years</td><td>Involuntary, repetitive movements (especially orofacial: lip smacking, tongue protrusion, chewing, grimacing); may be irreversible</td><td>Discontinue or reduce offending agent if possible; valbenazine (Ingrezza) or deutetrabenazine (Austedo) -- VMAT2 inhibitors approved for TD</td></tr>
        </table>
        <div class="clinical-note">
          <strong>EPPP Tip</strong>
          <p>Know the timeline: acute dystonia appears within <strong>hours to days</strong>, akathisia within <strong>days to weeks</strong>, parkinsonism within <strong>weeks to months</strong>, and tardive dyskinesia after <strong>months to years</strong> of use. TD is the most feared because it may be <strong>irreversible</strong> and paradoxically may worsen when the offending drug is discontinued.</p>
        </div>
      </section>

      <section class="content-section">
        <h2>Neuroleptic Malignant Syndrome (NMS)</h2>
        <div class="definition-box">
          <strong>Neuroleptic Malignant Syndrome (NMS)</strong>
          <p><span class="key-term">NMS</span> is a rare but life-threatening medical emergency caused by antipsychotic medications (especially high-potency typicals, but can occur with any antipsychotic). Mortality rate is approximately 10-20% if untreated.</p>
        </div>
        <h3>Clinical Features of NMS (mnemonic: FEVER)</h3>
        <ul>
          <li><strong>F</strong>ever (hyperthermia, often >40C/104F)</li>
          <li><strong>E</strong>ncephalopathy (altered mental status, confusion, delirium)</li>
          <li><strong>V</strong>itals unstable (autonomic instability: tachycardia, labile blood pressure, diaphoresis)</li>
          <li><strong>E</strong>levated enzymes (elevated creatine phosphokinase/CPK from muscle breakdown)</li>
          <li><strong>R</strong>igidity (severe "lead pipe" muscle rigidity)</li>
        </ul>
        <h3>Treatment of NMS</h3>
        <ul>
          <li>Immediate discontinuation of the antipsychotic</li>
          <li>Supportive care (cooling, IV fluids, cardiac monitoring)</li>
          <li><strong>Dantrolene</strong> (muscle relaxant) for rigidity</li>
          <li><strong>Bromocriptine</strong> (dopamine agonist) to restore dopaminergic activity</li>
          <li>Benzodiazepines may be used adjunctively</li>
        </ul>
        <div class="example-box">
          <strong>NMS vs. Serotonin Syndrome</strong>
          <p>Both involve hyperthermia and altered mental status, but NMS features <strong>lead-pipe rigidity</strong> and develops over <strong>days</strong>, while serotonin syndrome features <strong>hyperreflexia, clonus, and myoclonus</strong> and develops within <strong>hours</strong>. NMS is caused by dopamine blockade; serotonin syndrome by serotonin excess.</p>
        </div>
      </section>

      <section class="content-section">
        <h2>Second-Generation (Atypical) Antipsychotics</h2>
        <p><span class="key-term">Atypical antipsychotics</span> block both dopamine D2 receptors and serotonin 5-HT2A receptors. This dual mechanism, known as <span class="key-term">serotonin-dopamine antagonism (SDA)</span>, is thought to reduce EPS risk and improve negative symptoms compared to typical antipsychotics.</p>

        <h3>Common Atypical Antipsychotics</h3>
        <table>
          <tr><th>Generic Name</th><th>Brand Name</th><th>Notable Features</th></tr>
          <tr><td>Clozapine</td><td>Clozaril</td><td>Gold standard for <strong>treatment-resistant schizophrenia</strong>; lowest EPS risk; most effective for refractory positive and negative symptoms; also reduces suicidality in schizophrenia. SERIOUS RISK: <strong>agranulocytosis</strong> (1-2%) requiring mandatory blood monitoring (weekly for 6 months, then biweekly, then monthly)</td></tr>
          <tr><td>Risperidone</td><td>Risperdal</td><td>Higher EPS risk than other atypicals at higher doses (dose-dependent D2 blockade); significant prolactin elevation; available as long-acting injectable (Risperdal Consta)</td></tr>
          <tr><td>Olanzapine</td><td>Zyprexa</td><td>Highest risk of <strong>weight gain and metabolic syndrome</strong>; structurally similar to clozapine; effective but metabolic concerns limit use</td></tr>
          <tr><td>Quetiapine</td><td>Seroquel</td><td>Very sedating at lower doses; used off-label for insomnia and anxiety; lower EPS risk; less prolactin elevation</td></tr>
          <tr><td>Ziprasidone</td><td>Geodon</td><td>Weight-neutral; lowest metabolic risk among atypicals; QT prolongation concern; should be taken with food for absorption</td></tr>
          <tr><td>Aripiprazole</td><td>Abilify</td><td><strong>Partial dopamine agonist</strong> (D2 partial agonist); stabilizes dopamine activity; low EPS, low metabolic risk, low sedation; may cause akathisia</td></tr>
          <tr><td>Lurasidone</td><td>Latuda</td><td>Must be taken with food (350+ calories); lower metabolic risk; approved for bipolar depression</td></tr>
        </table>
        <div class="clinical-note">
          <strong>EPPP Tip</strong>
          <p>Key facts to know: <strong>Clozapine</strong> = treatment-resistant schizophrenia + agranulocytosis risk + mandatory blood monitoring. <strong>Olanzapine</strong> = worst metabolic side effects. <strong>Aripiprazole</strong> = unique partial D2 agonist mechanism. <strong>Risperidone</strong> = highest prolactin elevation among atypicals.</p>
        </div>
      </section>

      <section class="content-section">
        <h2>Metabolic Syndrome</h2>
        <p>Second-generation antipsychotics (especially clozapine and olanzapine) carry significant risk of <span class="key-term">metabolic syndrome</span>, which includes:</p>
        <ul>
          <li><strong>Weight gain</strong> (often 10-30+ pounds)</li>
          <li><strong>Dyslipidemia</strong> (elevated triglycerides, decreased HDL)</li>
          <li><strong>Hyperglycemia / Type 2 diabetes</strong></li>
          <li><strong>Hypertension</strong></li>
        </ul>
        <p>Metabolic monitoring (fasting glucose, lipid panel, weight, waist circumference, blood pressure) is recommended at baseline and at regular intervals for all patients on atypical antipsychotics.</p>
        <h3>Metabolic Risk by Medication (High to Low)</h3>
        <ol>
          <li>Clozapine and Olanzapine (highest risk)</li>
          <li>Quetiapine and Risperidone (moderate risk)</li>
          <li>Aripiprazole, Ziprasidone, and Lurasidone (lowest risk)</li>
        </ol>
      </section>

      <section class="content-section">
        <h2>Comparing Typical vs. Atypical Antipsychotics</h2>
        <table>
          <tr><th>Feature</th><th>Typical (First-Gen)</th><th>Atypical (Second-Gen)</th></tr>
          <tr><td>Primary mechanism</td><td>D2 blockade</td><td>D2 + 5-HT2A blockade</td></tr>
          <tr><td>Positive symptoms</td><td>Effective</td><td>Effective</td></tr>
          <tr><td>Negative symptoms</td><td>Less effective; may worsen</td><td>More effective</td></tr>
          <tr><td>EPS risk</td><td>Higher (especially high-potency)</td><td>Lower (except risperidone at high doses)</td></tr>
          <tr><td>Tardive dyskinesia risk</td><td>Higher</td><td>Lower (but still possible)</td></tr>
          <tr><td>Metabolic syndrome risk</td><td>Lower</td><td>Higher (especially clozapine, olanzapine)</td></tr>
          <tr><td>Prolactin elevation</td><td>Common</td><td>Variable (highest with risperidone)</td></tr>
          <tr><td>Sedation</td><td>Common (low potency)</td><td>Variable (quetiapine most sedating)</td></tr>
        </table>
      </section>

      <section class="content-section">
        <h2>Key Takeaways for the EPPP</h2>
        <ul>
          <li>Typical antipsychotics work via <strong>D2 blockade</strong>; atypicals combine <strong>D2 and 5-HT2A blockade</strong>.</li>
          <li>High-potency typicals (haloperidol) = high EPS risk, low sedation. Low-potency typicals (chlorpromazine) = low EPS risk, high sedation.</li>
          <li><strong>EPS timeline:</strong> acute dystonia (hours-days), akathisia (days-weeks), parkinsonism (weeks-months), tardive dyskinesia (months-years).</li>
          <li><strong>NMS</strong> is a medical emergency: hyperthermia, lead-pipe rigidity, autonomic instability, elevated CPK. Treat with dantrolene and bromocriptine.</li>
          <li><strong>Clozapine</strong> is the gold standard for treatment-resistant schizophrenia but requires blood monitoring for agranulocytosis.</li>
          <li><strong>Olanzapine</strong> has the highest metabolic risk among commonly used atypicals.</li>
          <li><strong>Aripiprazole</strong> is unique as a partial D2 agonist.</li>
          <li>Metabolic monitoring is recommended for all patients on atypical antipsychotics.</li>
          <li><strong>Tardive dyskinesia</strong> may be irreversible and can worsen when the offending drug is stopped.</li>
        </ul>
      </section>
      <div class="nav-buttons">
        <a href="antidepressants.html" class="nav-btn">
          <svg viewBox="0 0 24 24" width="20" height="20" fill="none" stroke="currentColor" stroke-width="2"><path d="M15 18l-6-6 6-6"/></svg>
          <div>
            <div class="nav-btn-label">Previous</div>
            <div class="nav-btn-title">Antidepressants</div>
          </div>
        </a>
        <a href="anxiolytics-sedatives.html" class="nav-btn">
          <div style="text-align: right;">
            <div class="nav-btn-label">Next</div>
            <div class="nav-btn-title">Anxiolytics & Sedatives</div>
          </div>
          <svg viewBox="0 0 24 24" width="20" height="20" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        </a>
      </div>
    </main>
  </div>
  <div class="upgrade-modal-overlay" id="upgradeModal" onclick="if(event.target===this)this.classList.remove('visible')">
    <div class="upgrade-modal">
      <div class="upgrade-modal-icon"><svg width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polygon points="12 2 15.09 8.26 22 9.27 17 14.14 18.18 21.02 12 17.77 5.82 21.02 7 14.14 2 9.27 8.91 8.26 12 2"/></svg></div>
      <h3>Upgrade to Unlock</h3>
      <p>Flashcards, Quick Quizzes, and Mastery Quizzes are available on paid plans. Upgrade today to test your knowledge and track your progress.</p>
      <div class="upgrade-modal-actions">
        <button class="btn-dismiss" onclick="document.getElementById('upgradeModal').classList.remove('visible')">Maybe Later</button>
        <a href="../../index.html" class="btn-upgrade">View Plans</a>
      </div>
    </div>
  </div>
  <script>
    function chapterAction(action, domainNum) {
      var tier = 'free';
      try {
        var s = sessionStorage.getItem('passeppp_session');
        if (s) { tier = JSON.parse(s).tier || 'free'; }
      } catch(e) {}
      if (tier === 'free') {
        document.getElementById('upgradeModal').classList.add('visible');
        return;
      }
      if (action === 'flashcards') window.location.href = '../../index.html';
      else if (action === 'quiz-fundamental') window.location.href = '../../index.html';
      else if (action === 'advanced-learning') { var ch = document.querySelector('h1').textContent.trim(); window.location.href = '../../index.html'; }
    }
  </script>
</body>
</html>
